<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Epidemiology and Infectious Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Epidemiology and Infectious Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Эпидемиология и инфекционные болезни</trans-title></trans-title-group></journal-title-group><issn publication-format="print">3034-2007</issn><issn publication-format="electronic">3034-2015</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">629244</article-id><article-id pub-id-type="doi">10.17816/EID629244</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The possibility of predicting the COVID-19 severity by clinical-laboratory criteria taking into account the SARS-CoV-2 strain: An analytical review</article-title><trans-title-group xml:lang="ru"><trans-title>Возможность прогнозирования тяжести течения COVID-19 по клинико-лабораторным критериям с учётом штамма SARS-CoV-2: аналитический обзор</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5053-0312</contrib-id><contrib-id contrib-id-type="spin">7290-8377</contrib-id><name-alternatives><name xml:lang="en"><surname>Poluektova</surname><given-names>Victoria B.</given-names></name><name xml:lang="ru"><surname>Полуэктова</surname><given-names>Виктория Борисовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>viktoriya211@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3164-9737</contrib-id><contrib-id contrib-id-type="spin">2212-5646</contrib-id><name-alternatives><name xml:lang="en"><surname>Sankova</surname><given-names>Maria V.</given-names></name><name xml:lang="ru"><surname>Санькова</surname><given-names>Мария Вячеславовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>cankov@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4581-4510</contrib-id><contrib-id contrib-id-type="spin">3342-4681</contrib-id><name-alternatives><name xml:lang="en"><surname>Volchkova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Волчкова</surname><given-names>Елена Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>antononina@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0188-543X</contrib-id><contrib-id contrib-id-type="spin">2906-0605</contrib-id><name-alternatives><name xml:lang="en"><surname>Larina</surname><given-names>Svetlana N.</given-names></name><name xml:lang="ru"><surname>Ларина</surname><given-names>Светлана Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biology), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. биол. наук, доцент</p></bio><email>snlarina07@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0430-731X</contrib-id><contrib-id contrib-id-type="spin">8267-9750</contrib-id><name-alternatives><name xml:lang="en"><surname>Maloletneva</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Малолетнева</surname><given-names>Наталья Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>natalya-maloletneva@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0506-0961</contrib-id><contrib-id contrib-id-type="spin">5773-4882</contrib-id><name-alternatives><name xml:lang="en"><surname>Shabalina</surname><given-names>Olga Yu.</given-names></name><name xml:lang="ru"><surname>Шабалина</surname><given-names>Ольга Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>shoy3020@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2009-8354</contrib-id><name-alternatives><name xml:lang="en"><surname>Lisova</surname><given-names>Polina A.</given-names></name><name xml:lang="ru"><surname>Лисова</surname><given-names>Полина Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>paolino31@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7677-2969</contrib-id><name-alternatives><name xml:lang="en"><surname>Rochlina</surname><given-names>Daria A.</given-names></name><name xml:lang="ru"><surname>Рохлина</surname><given-names>Дарья Александровна</given-names></name></name-alternatives><bio xml:lang="en"><p>MD</p></bio><email>dasharohlina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8496-3987</contrib-id><contrib-id contrib-id-type="spin">1561-9961</contrib-id><name-alternatives><name xml:lang="en"><surname>Darvina</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Дарвина</surname><given-names>Ольга Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>oldarmir@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-06-18" publication-format="electronic"><day>18</day><month>06</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2024</year></pub-date><volume>29</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>192</fpage><lpage>203</lpage><history><date date-type="received" iso-8601-date="2024-03-19"><day>19</day><month>03</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-04-22"><day>22</day><month>04</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Eco-vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Эко-вектор</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Eco-vector</copyright-holder><copyright-holder xml:lang="ru">Эко-вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-06-18"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://rjeid.com/1560-9529/article/view/629244">https://rjeid.com/1560-9529/article/view/629244</self-uri><abstract xml:lang="en"><p>The survival of patients with severe COVID-19 depends on timely and adequate assessment of the risk of adverse disease outcomes. Currently, conflicting data on the prognostic value of various laboratory parameters in severe COVID-19 caused by different SARS-CoV-2 variants require analysis and systematization. The leading clinical and laboratory signs that determine the severity of COVID-19 include the syndrome of systemic inflammatory reaction and hemostasis disorders, which, in conditions of high viral load, hypoxia, and toxic exposure, contribute to the development of cytolytic syndrome, cytopenia, and multiple organ failure. Biological and immunological features of SARS-CoV-2 variants have an important influence on the severity of the infection. Based on literature sources, we have listed the most significant laboratory parameters, which, combined with clinical criteria, serve as an accurate guide for physicians both in monitoring patients and selecting therapy in Russia and abroad. Some SARS-CoV-2 variants exhibit reduced susceptibility to monoclonal antibodies and recombination plasma, which requires a revision of the therapy strategy. Detailed analysis of pathognomonic laboratory parameters and understanding of the immunological response to a particular SARS-CoV-2 variant will quickly and accurately identify the vulnerable patient groups, timely change in their therapy, and prevent complication development.</p></abstract><trans-abstract xml:lang="ru"><p>Выживаемость пациентов с COVID-19 тяжёлого течения зависит от своевременной и адекватной оценки риска развития неблагоприятного исхода заболевания. Накопившееся в настоящее время большое количество противоречивых данных о прогностическом значении различных лабораторных показателей при тяжёлом течении COVID-19, вызываемого различными штаммами SARS-CoV-2, требует их анализа и систематизации. Показано, что ведущими клинико-лабораторными признаками, определяющими тяжесть течения COVID-19, являются синдром системной воспалительной реакции и нарушения гемостаза, которые в условиях высокой вирусной нагрузки, гипоксии и токсического воздействия способствуют развитию цитолитического синдрома, цитопении и полиорганной недостаточности. Немаловажное влияние на тяжесть течения инфекционного процесса оказывают биологические и иммунологические особенности различных штаммов SARS-CoV-2. На основании литературных источников перечислены общепринятые в нашей стране и за рубежом наиболее значимые лабораторные показатели, которые в сочетании с клиническими критериями служат точным ориентиром для врачей как при наблюдении за состоянием пациентов, так и для подбора терапии. Некоторые из штаммов возбудителя SARS-CoV-2 демонстрируют пониженную восприимчивость к моноклональным антителам и реконвалесцентной плазме, что требует пересмотра стратегии терапии. Детальный анализ патогномоничных лабораторных параметров и понимание иммунологического ответа на конкретный штамм возбудителя SARS-CoV-2 позволят быстро и точно выявить уязвимые группы пациентов, своевременно изменить у них проводимую терапию и предотвратить развитие осложнений.</p></trans-abstract><kwd-group xml:lang="en"><kwd>severe COVID-19</kwd><kwd>laboratory predictors</kwd><kwd>SARS-CoV-2 strains</kwd><kwd>Wuhan strain</kwd><kwd>alpha variant</kwd><kwd>beta variant</kwd><kwd>gamma variant</kwd><kwd>delta variant</kwd><kwd>omicron variant</kwd><kwd>COVID-19 treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>тяжёлое течение COVID-19</kwd><kwd>лабораторные предикторы</kwd><kwd>штаммы SARS-CoV-2</kwd><kwd>уханьский штамм</kwd><kwd>альфа-вариант</kwd><kwd>бета-вариант</kwd><kwd>гамма-вариант</kwd><kwd>дельта-вариант</kwd><kwd>омикрон-вариант</kwd><kwd>лечение COVID-19</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Temporary methodological recommendations: prevention, diagnosis and treatment of new coronary infection (COVID-19). Version 17 (14.12.2022). Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/ВМР_COVID-19_V17.pdf (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 17 (14.12.2022). Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/252/original/ВМР_COVID-19_V17.pdf</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157–160. doi: 10.23750/abm.v91i1.9397</mixed-citation><mixed-citation xml:lang="ru">Cucinotta D., Vanelli M. WHO Declares COVID-19 a Pandemic // Acta Biomed. 2020. Vol. 91, N 1. P. 157–160. doi: 10.23750/abm.v91i1.9397</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Saberiyan M, Karimi E, Khademi Z, et al. SARS-CoV-2: phenotype, genotype, and characterization of different variants. Cell Mol Biol Lett. 2022;27(1):50. doi: 10.1186/s11658-022-00352-6</mixed-citation><mixed-citation xml:lang="ru">Saberiyan M., Karimi E., Khademi Z., et al. SARS-CoV-2: phenotype, genotype, and characterization of different variants // Cell Mol Biol Lett. 2022. Vol. 27, N 1. P. 50. doi: 10.1186/s11658-022-00352-6</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi: 10.1016/S2213-2600(20)30079-5</mixed-citation><mixed-citation xml:lang="ru">Yang X., Yu Y., Xu J., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study // Lancet Respir Med. 2020. Vol. 8, N 5. P. 475–481. doi: 10.1016/S2213-2600(20)30079-5</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Guan WJ, Ni ZY, Hu Y, et al.; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032</mixed-citation><mixed-citation xml:lang="ru">Guan W.-J., Ni Z.-Y., Hu Y., et al.; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China // N Engl J Med. 2020. Vol. 382, N 18. P. 1708–1720. doi: 10.1056/NEJMoa2002032</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi: 10.1172/JCI137244</mixed-citation><mixed-citation xml:lang="ru">Chen G., Wu D., Guo W., et al. Clinical and immunological features of severe and moderate coronavirus disease 2019 // J Clin Invest. 2020. Vol. 130, N 5. P. 2620–2629. doi: 10.1172/JCI137244</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol. 2020;92(11):2283–2285. doi: 10.1002/jmv.25948</mixed-citation><mixed-citation xml:lang="ru">Aziz M., Fatima R., Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis // J Med Virol. 2020. Vol. 92, N 11. P. 2283–2285. doi: 10.1002/jmv.25948</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Khizroeva JH, Makatsariya AD, Bitsadze VO, et al. Laboratory monitoring of COVID-19 patients and importance of coagulopathy markers. Obstetrics, Gynecology and Reproduction. 2020;14(2): 132–147. (In Russ.) doi: 10.17749/2313-7347.141</mixed-citation><mixed-citation xml:lang="ru">Хизроева Д.Х., Макацария А.Д., Бицадзе В.О., и др. Лабораторный мониторинг COVID-19 и значение определения маркеров коагулопатии // Акушерство, Гинекология и Репродукция. 2020. Т. 14, № 2. С. 132–147. doi: 10.17749/2313-7347.141</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370. doi: 10.1016/j.jcv.2020.104370</mixed-citation><mixed-citation xml:lang="ru">Liu F., Li L., Xu M., et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 // J Clin Virol. 2020. Vol. 127. P. 104370. doi: 10.1016/j.jcv.2020.104370</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. doi: 10.1016/j.jaci.2020.04.006</mixed-citation><mixed-citation xml:lang="ru">Li X., Xu S., Yu M., et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan // J Allergy Clin Immunol. 2020. Vol. 146, N 1. P. 110–118. doi: 10.1016/j.jaci.2020.04.006</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness. Am J Respir Crit Care Med. 2020;202(6):812–821. doi: 10.1164/rccm.202005-1583OC</mixed-citation><mixed-citation xml:lang="ru">McElvaney O.J., McEvoy N.L., McElvaney O.F., et al. Characterization of the Inflammatory Response to Severe COVID-19 Illness // Am J Respir Crit Care Med. 2020. Vol. 202, N 6. P. 812–821. doi: 10.1164/rccm.202005-1583OC</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131–1134. doi: 10.1515/cclm-2020-0198</mixed-citation><mixed-citation xml:lang="ru">Lippi G., Plebani M. Laboratory abnormalities in patients with COVID-2019 infection // Clin Chem Lab Med. 2020. Vol. 58, N 7. P. 1131–1134. doi: 10.1515/cclm-2020-0198</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Sack GH Jr. Serum amyloid A — a review. Mol Med. 2018;24(1):46. doi: 10.1186/s10020-018-0047-0</mixed-citation><mixed-citation xml:lang="ru">Sack G.H. Jr. Serum amyloid A — a review // Mol Med. 2018. Vol. 24, N 1. P. 46. doi: 10.1186/s10020-018-0047-0</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Cheng L, Li H, Li L, et al. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Lab Anal. 2020;34(10):e23618. doi: 10.1002/jcla.23618</mixed-citation><mixed-citation xml:lang="ru">Cheng L., Li H., Li L., et al. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis // J Clin Lab Anal. 2020. Vol. 34, N 10. P. e23618. doi: 10.1002/jcla.23618</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Taneri PE, Gómez-Ochoa SA, Llanaj E, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(8):763–773. doi: 10.1007/s10654-020-00678-5</mixed-citation><mixed-citation xml:lang="ru">Taneri P.E., Gómez-Ochoa S.A., Llanaj E., et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis // Eur J Epidemiol. 2020. Vol. 35, N 8. P. 763–773. doi: 10.1007/s10654-020-00678-5</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):33. doi: 10.1038/s41392-020-0148-4</mixed-citation><mixed-citation xml:lang="ru">Tan L., Wang Q., Zhang D., et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study // Signal Transduct Target Ther. 2020. Vol. 5, N 1. P. 33. doi: 10.1038/s41392-020-0148-4</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3</mixed-citation><mixed-citation xml:lang="ru">Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. 2020. Vol. 395, N 10229. P. 1054–1062. doi: 10.1016/S0140-6736(20)30566-3</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Lutckii AA, Zhirkov AA, Lobzin DYu, et al. Interferon-γ: biological function and application for study of cellular immune response. Journal Infectology. 2015;7(4):10–22. (In Russ.) doi: 10.22625/2072-6732-2015-7-4-10-22</mixed-citation><mixed-citation xml:lang="ru">Луцкий А.А., Жирков А.А., Лобзин Д.Ю., и др. Интерферон-γ: биологическая функция и значение для диагностики клеточного иммунного ответа // Журнал инфектологии. 2015. Т. 7, № 4. С. 10–22. doi: 10.22625/2072-6732-2015-7-4-10-22</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Klypa TV, Bychinin MV, Mandel IA, et al. Clinical characteristics of patients admitted to an ICU with COVID-19. Predictors of the severe disease. Journal of Clinical Practice. 2020;11(2):6–20. (In Russ.) doi: 10.17816/clinpract34182</mixed-citation><mixed-citation xml:lang="ru">Клыпа Т.В., Бычинин М.В., Мандель И.А., и др. Клиническая характеристика пациентов с COVID-19, поступающих в отделение интенсивной терапии. Предикторы тяжёлого течения // Клиническая практика. 2020. Т. 11, № 2. C. 6–20. doi: 10.17816/clinpract34182</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J Med Virol. 2020;92(10):1733–1734. doi: 10.1002/jmv.25819</mixed-citation><mixed-citation xml:lang="ru">Lagunas-Rangel F.A. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis // J Med Virol. 2020. Vol. 92, N 10. P. 1733–1734. doi: 10.1002/jmv.25819</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Pereira MAM, Barros ICA, Jacob ALV, et al. Laboratory findings in SARS-CoV-2 infections: State of the art. Rev Assoc Med Bras (1992). 2020;66(8):1152–1156. doi: 10.1590/1806-9282.66.8.1152</mixed-citation><mixed-citation xml:lang="ru">Pereira M.A.M., Barros I.C.A., Jacob A.L.V, et al. Laboratory findings in SARS-CoV-2 infections: State of the art // Rev Assoc Med Bras (1992). 2020. Vol. 66, N 8. P. 1152–1156. doi: 10.1590/1806-9282.66.8.1152</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Qu R, Ling Y, Zhang YHZ, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020;92(9):1533–1541. doi: 10.1002/jmv.25767</mixed-citation><mixed-citation xml:lang="ru">Qu R., Ling Y., Zhang Y.-H.-Z., et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19 // J Med Virol. 2020. Vol. 92, N 9. P. 1533–1541. doi: 10.1002/jmv.25767</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Spiezia L, Boscolo A, Poletto F, et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb Haemost. 2020;120(6):998–1000. doi: 10.1055/s-0040-1710018</mixed-citation><mixed-citation xml:lang="ru">Spiezia L., Boscolo A., Poletto F., et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure // Thromb Haemost. 2020. Vol. 120, N 6. P. 998–1000. doi: 10.1055/s-0040-1710018</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Makatsariya AD, Slukhanchuk EV, Bitsadze VO, et al. COVID-19, hemostasis disorders and risk of thrombotic complications. Annals of the Russian Academy of Medical sciences. 2020;75(4):306–317. (In Russ.) doi: 10.15690/vramn1368</mixed-citation><mixed-citation xml:lang="ru">Макацария А.Д., Слуханчук Е.В., Бицадзе В.О., и др. COVID-19, нарушения гемостаза и риск тромботических осложнений // Вестник Российской академии медицинских наук. 2020. Т. 75, № 4. С. 306–317. doi: 10.15690/vramn1368</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Ji HL, Zhao R, Matalon S, Matthay MA. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiol Rev. 2020;100(3):1065–1075. doi: 10.1152/physrev.00013.2020</mixed-citation><mixed-citation xml:lang="ru">Ji H.-L., Zhao R., Matalon S., Matthay M.A. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility // Physiol Rev. 2020. Vol. 100, N 3. P. 1065–1075. doi: 10.1152/physrev.00013.2020</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747–1751. doi: 10.1111/jth.14854</mixed-citation><mixed-citation xml:lang="ru">Ranucci M., Ballotta A., Di Dedda U., et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome // J Thromb Haemost. 2020. Vol. 18, N 7. P. 1747–1751. doi: 10.1111/jth.14854</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–1026. doi: 10.1111/jth.14810</mixed-citation><mixed-citation xml:lang="ru">Thachil J., Tang N., Gando S., et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19 // J Thromb Haemost. 2020. Vol. 18, N 5. P. 1023–1026. doi: 10.1111/jth.14810</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Aksenova A.Y. Von Willebrand factor and endothelial damage: a possible association with COVID-19. Ecological genetics. 2020;18(2):135–138. (In Russ.) doi: 10.17816/ecogen33973</mixed-citation><mixed-citation xml:lang="ru">Аксёнова А.Ю. Фактор Фон Виллебранда и повреждение эндотелия: возможная связь с COVID-19 // Экологическая генетика. 2020. Т. 18, № 2. С. 135–138. doi: 10.17816/ecogen33973</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Yang Z, Shi J, He Z, et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Aging (Albany NY). 2020;12(7):6037–6048. doi: 10.18632/aging.102999</mixed-citation><mixed-citation xml:lang="ru">Yang Z., Shi J., He Z., et al. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients // Aging (Albany NY). 2020. Vol. 12, N 7. P. 6037–6048. doi: 10.18632/aging.102999</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Misra A, Ghosh A, Gupta R. Heterogeneity in presentation of hyperglycaemia during COVID-19 pandemic: A proposed classification. Diabetes Metab Syndr. 2021;15(1):403–406. doi: 10.1016/j.dsx.2021.01.018</mixed-citation><mixed-citation xml:lang="ru">Misra A., Ghosh A., Gupta R. Heterogeneity in presentation of hyperglycaemia during COVID-19 pandemic: A proposed classification // Diabetes Metab Syndr. 2021. Vol. 15, N 1. P. 403–406. doi: 10.1016/j.dsx.2021.01.018</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Klypa TV, Orehova MS, Zabrosaeva LI. Hyperglycaemia in criticaly ill patients. Diabetes mellitus. 2015;18(1):33–41. (In Russ.) doi: 10.14341/DM2015133-41</mixed-citation><mixed-citation xml:lang="ru">Клыпа Т.В., Орехова М.С., Забросаева Л.И. Гипергликемия критических состояний // Сахарный диабет. 2015. Т. 18, № 1. С. 33–41. doi: 10.14341/DM2015133-41</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020;11(7):995–998. doi: 10.1021/acschemneuro.0c00122</mixed-citation><mixed-citation xml:lang="ru">Baig A.M., Khaleeq A., Ali U., Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms // ACS Chem Neurosci. 2020. Vol. 11, N 7. P. 995–998. doi: 10.1021/acschemneuro.0c00122</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18–22. doi: 10.1016/j.bbi.2020.03.031</mixed-citation><mixed-citation xml:lang="ru">Wu Y., Xu X., Chen Z., et al. Nervous system involvement after infection with COVID-19 and other coronaviruses // Brain Behav Immun. 2020. Vol. 87. P. 18–22. doi: 10.1016/j.bbi.2020.03.031</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Mohammad S, Mishra A, Ashraf MZ. Emerging Role of Vitamin D and its Associated Molecules in Pathways Related to Pathogenesis of Thrombosis. Biomolecules. 2019;9(11):649. doi: 10.3390/biom9110649</mixed-citation><mixed-citation xml:lang="ru">Mohammad S., Mishra A., Ashraf M.Z. Emerging Role of Vitamin D and its Associated Molecules in Pathways Related to Pathogenesis of Thrombosis // Biomolecules. 2019. Vol. 9, N 11. P. 649. doi: 10.3390/biom9110649</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Gubenko NS, Budko AA, Plisyuk AG, Orlova IA. Association of general blood count indicators with the severity of COVID-19 in hospitalized patients. South Russian Journal of Therapeutic Practice. 2021;2(1):90–101. (In Russ.) doi: 10.21886/2712-8156-2021-2-1-90-101</mixed-citation><mixed-citation xml:lang="ru">Губенко Н.С., Будко А.А., Плисюк А.Г., Орлова Я.А. Связь показателей общего анализа крови с тяжестью течения COVID-19 у госпитализированных пациентов // Южно-Российский журнал терапевтической практики. 2021. Т. 2, № 1. С. 90–101. doi: 10.21886/2712-8156-2021-2-1-90-101</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Simon J, Grodecki K, Cadet S, et al. Radiomorphological signs and clinical severity of SARS-CoV-2 lineage B.1.1.7. BJR Open. 2022;4(1):20220016. doi: 10.1259/bjro.20220016</mixed-citation><mixed-citation xml:lang="ru">Simon J., Grodecki K., Cadet S., et al. Radiomorphological signs and clinical severity of SARS-CoV-2 lineage B.1.1.7 // BJR Open. 2022. Vol. 4, N 1. P. 20220016. doi: 10.1259/bjro.20220016</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Akkız H. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern. Front Med (Lausanne). 2022;9:849217. doi: 10.3389/fmed.2022.849217</mixed-citation><mixed-citation xml:lang="ru">Akkız H. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern // Front Med (Lausanne). 2022. Vol. 9. P. 849217. doi: 10.3389/fmed.2022.849217</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Gupta RK. Will SARS-CoV-2 variants of concern affect the promise of vaccines? Nat Rev Immunol. 2021;21(6):340–341. doi: 10.1038/s41577-021-00556-5</mixed-citation><mixed-citation xml:lang="ru">Gupta R.K. Will SARS-CoV-2 variants of concern affect the promise of vaccines? // Nat Rev Immunol. 2021. Vol. 21, N 6. P. 340–341. doi: 10.1038/s41577-021-00556-5</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">Hirabara SM, Serdan TDA, Gorjao R, et al. SARS-COV-2 Variants: Differences and Potential of Immune Evasion. Front Cell Infect Microbiol. 2022;11:781429. doi: 10.3389/fcimb.2021.781429</mixed-citation><mixed-citation xml:lang="ru">Hirabara S.M., Serdan T.D.A., Gorjao R., et al. SARS-COV-2 Variants: Differences and Potential of Immune Evasion // Front Cell Infect Microbiol. 2022. Vol. 11. P. 781429. doi: 10.3389/fcimb.2021.781429</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Van Goethem N, Vandromme M, Van Oyen H, et al. Severity of infection with the SARS-CoV-2 B.1.1.7 lineage among hospitalized COVID-19 patients in Belgium. PLoS One. 2022;17(6):e0269138. doi: 10.1371/journal.pone.0269138</mixed-citation><mixed-citation xml:lang="ru">Van Goethem N., Vandromme M., Van Oyen H., et al. Severity of infection with the SARS-CoV-2 B.1.1.7 lineage among hospitalized COVID-19 patients in Belgium // PLoS One. 2022. Vol. 17, N 6. P. e0269138. doi: 10.1371/journal.pone.0269138</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">Giles B, Meredith P, Robson S, et al. The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out. Lancet Infect Dis. 2021;21(9):1213–1214. doi: 10.1016/S1473-3099(21)00356-X</mixed-citation><mixed-citation xml:lang="ru">Giles B., Meredith P., Robson S., et al. The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out // Lancet Infect Dis. 2021. Vol. 21, N 9. P. 1213–1214. doi: 10.1016/S1473-3099(21)00356-X</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">Spinicci M, Graziani L, Tilli M, et al. Infection with SARS-CoV-2 Variants Is Associated with Different Long COVID Phenotypes. Viruses. 2022;14(11):2367. doi: 10.3390/v14112367</mixed-citation><mixed-citation xml:lang="ru">Spinicci M., Graziani L., Tilli M., et al. Infection with SARS-CoV-2 Variants Is Associated with Different Long COVID Phenotypes // Viruses. 2022. Vol. 14, N 11. P. 2367. doi: 10.3390/v14112367</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Funk T, Pharris A, Spiteri G, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill. 2021;26(16):2100348. doi: 10.2807/1560-7917.ES.2021.26.16.2100348</mixed-citation><mixed-citation xml:lang="ru">Funk T., Pharris A., Spiteri G., et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021 // Euro Surveill. 2021. Vol. 26, N 16. P. 2100348. doi: 10.2807/1560-7917.ES.2021.26.16.2100348</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">Conti P, Caraffa A, Gallenga CE, et al. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. J Biol Regul Homeost Agents. 2021;35(1):1–4. doi: 10.23812/21-3-E</mixed-citation><mixed-citation xml:lang="ru">Conti P., Caraffa A., Gallenga C.E., et al. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem // J Biol Regul Homeost Agents. 2021. Vol. 35, N 1. P. 1–4. doi: 10.23812/21-3-E</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021;27(4):622–625. doi: 10.1038/s41591-021-01285-x</mixed-citation><mixed-citation xml:lang="ru">Wibmer C.K., Ayres F., Hermanus T., et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma // Nat Med. 2021. Vol. 27, N 4. P. 622–625. doi: 10.1038/s41591-021-01285-x</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">Khan A, Khan T, Ali S, et al. SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines. Biomed Pharmacother. 2021;143:112176. doi: 10.1016/j.biopha.2021.112176</mixed-citation><mixed-citation xml:lang="ru">Khan A., Khan T., Ali S., et al. SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines // Biomed Pharmacother. 2021. Vol. 143. P. 112176. doi: 10.1016/j.biopha.2021.112176</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">Duong D. Alpha, Beta, Delta, Gamma: what’s important to know about SARS-CoV-2 variants of concern? CMAJ. 2021;193(27): E1059–E1060. doi: 10.1503/cmaj.1095949</mixed-citation><mixed-citation xml:lang="ru">Duong D. Alpha, Beta, Delta, Gamma: what’s important to know about SARS-CoV-2 variants of concern? // CMAJ. 2021. Vol. 193, N 27. P. E1059–E1060. doi: 10.1503/cmaj.1095949</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–135. doi: 10.1038/s41586-021-03398-2</mixed-citation><mixed-citation xml:lang="ru">Wang P., Nair M.S., Liu L., et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 // Nature. 2021. Vol. 593, N 7857. P. 130–135. doi: 10.1038/s41586-021-03398-2</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">Ong SWX, Chiew CJ, Ang LW, et al. Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clin Infect Dis. 2022;75(1):e1128–e1136. doi: 10.1093/cid/ciab721</mixed-citation><mixed-citation xml:lang="ru">Ong S.W.X., Chiew C.J., Ang L.W., et al. Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta) // Clin Infect Dis. 2022. Vol. 75, N 1. P. e1128–e1136. doi: 10.1093/cid/ciab721</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><citation-alternatives><mixed-citation xml:lang="en">Esper FP, Adhikari TM, Tu ZJ, et al. Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants. J Infect Dis. 2023;227(3):344–352. doi: 10.1093/infdis/jiac411</mixed-citation><mixed-citation xml:lang="ru">Esper F.P., Adhikari T.M., Tu Z.J., et al. Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants // J Infect Dis. 2023. Vol. 227, N 3. P. 344–352. doi: 10.1093/infdis/jiac411</mixed-citation></citation-alternatives></ref><ref id="B51"><label>51.</label><citation-alternatives><mixed-citation xml:lang="en">Gökharman FD, Ertem GT, Aydın S, et al. Evaluation of thorax computed tomographic findings in COVID-19 variant cases. Respir Investig. 2022;60(3):364–368. doi: 10.1016/j.resinv.2021.11.013</mixed-citation><mixed-citation xml:lang="ru">Gökharman F.D., Ertem G.T., Aydın S., et al. Evaluation of thorax computed tomographic findings in COVID-19 variant cases // Respir Investig. 2022. Vol. 60, N 3. P. 364–368. doi: 10.1016/j.resinv.2021.11.013</mixed-citation></citation-alternatives></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">Wang P, Casner RG, Nair MS, et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. Cell Host Microbe. 2021;29(5):747–751.e4. doi: 10.1016/j.chom.2021.04.007</mixed-citation><mixed-citation xml:lang="ru">Wang P., Casner R.G., Nair M.S., et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization // Cell Host Microbe. 2021. Vol. 29, N 5. P. 747–751.e4. doi: 10.1016/j.chom.2021.04.007</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><citation-alternatives><mixed-citation xml:lang="en">Adam D. The rush to study fast-spreading coronavirus variants. Nature. 2021;594(7861):19–20. doi: 10.1038/d41586-021-01390-4</mixed-citation><mixed-citation xml:lang="ru">Adam D. The rush to study fast-spreading coronavirus variants // Nature. 2021. Vol. 594, N 7861. P. 19–20. doi: 10.1038/d41586-021-01390-4</mixed-citation></citation-alternatives></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">Viceconte G, Ponsiglione A, Buonomo AR, et al. COVID-19 chest CT and laboratory features of B.1.617.2 (Delta variant) vs B.1.1.7 (Alpha variant) surge: a single center case-control study. Infez Med. 2022;30(4):555–562. doi: 10.53854/liim-3004-10</mixed-citation><mixed-citation xml:lang="ru">Viceconte G., Ponsiglione A., Buonomo A.R., et al. COVID-19 chest CT and laboratory features of B.1.617.2 (Delta variant) vs B.1.1.7 (Alpha variant) surge: a single center case-control study // Infez Med. 2022. Vol. 30, N 4. P. 555–562. doi: 10.53854/liim-3004-10</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">Koc I. Clinical and Laboratory Differences between Delta and UK Variants of SARS-CoV-2: B.1.617.2 and B.1.1.7. Tohoku J Exp Med. 2022;257(4):273–281. doi: 10.1620/tjem.2022.J041</mixed-citation><mixed-citation xml:lang="ru">Koc I. Clinical and Laboratory Differences between Delta and UK Variants of SARS-CoV-2: B.1.617.2 and B.1.1.7 // Tohoku J Exp Med. 2022. Vol. 257, N 4. P. 273–281. doi: 10.1620/tjem.2022.J041</mixed-citation></citation-alternatives></ref><ref id="B56"><label>56.</label><citation-alternatives><mixed-citation xml:lang="en">Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871): 273–275. doi: 10.1038/s41586-021-03693-y</mixed-citation><mixed-citation xml:lang="ru">Liu J., Liu Y., Xia H., et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants // Nature. 2021. Vol. 596, N 7871. P. 273–275. doi: 10.1038/s41586-021-03693-y</mixed-citation></citation-alternatives></ref><ref id="B57"><label>57.</label><citation-alternatives><mixed-citation xml:lang="en">Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–280. doi: 10.1038/s41586-021-03777-9</mixed-citation><mixed-citation xml:lang="ru">Planas D., Veyer D., Baidaliuk A., et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization // Nature. 2021. Vol. 596, N 7871. P. 276–280. doi: 10.1038/s41586-021-03777-9</mixed-citation></citation-alternatives></ref><ref id="B58"><label>58.</label><citation-alternatives><mixed-citation xml:lang="en">Tong C, Shi W, Zhang A, Shi Z. Tracking and controlling the spatiotemporal spread of SARS-CoV-2 Omicron variant in South Africa. Travel Med Infect Dis. 2022;46:102252. doi: 10.1016/j.tmaid.2021.102252</mixed-citation><mixed-citation xml:lang="ru">Tong C., Shi W., Zhang A., Shi Z. Tracking and controlling the spatiotemporal spread of SARS-CoV-2 Omicron variant in South Africa // Travel Med Infect Dis. 2022. Vol. 46. P. 102252. doi: 10.1016/j.tmaid.2021.102252</mixed-citation></citation-alternatives></ref><ref id="B59"><label>59.</label><citation-alternatives><mixed-citation xml:lang="en">Chen J, Wang R, Gilby NB, Wei GW. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model. 2022;62(2):412–422. doi: 10.1021/acs.jcim.1c01451</mixed-citation><mixed-citation xml:lang="ru">Chen J., Wang R., Gilby N.B., Wei G.-W. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance // J Chem Inf Model. 2022. Vol. 62, N 2. P. 412–422. doi: 10.1021/acs.jcim.1c01451</mixed-citation></citation-alternatives></ref><ref id="B60"><label>60.</label><citation-alternatives><mixed-citation xml:lang="en">Jang YR, Kim JM, Rhee JE, et al. Clinical Features and Duration of Viral Shedding in Individuals With SARS-CoV-2 Omicron Variant Infection. Open Forum Infect Dis. 2022;9(7):ofac237. doi: 10.1093/ofid/ofac237</mixed-citation><mixed-citation xml:lang="ru">Jang Y.R., Kim J.-M., Rhee J.E., et al. Clinical Features and Duration of Viral Shedding in Individuals With SARS-CoV-2 Omicron Variant Infection // Open Forum Infect Dis. 2022. Vol. 9, N 7. P. ofac237. doi: 10.1093/ofid/ofac237</mixed-citation></citation-alternatives></ref><ref id="B61"><label>61.</label><citation-alternatives><mixed-citation xml:lang="en">Rodriguez-Sevilla JJ, Güerri-Fernádez R, Bertran Recasens B. Is There Less Alteration of Smell Sensation in Patients with Omicron SARS-CoV-2 Variant Infection? Front Med. 2022;9:852998. doi: 10.3389/fmed.2022.852998</mixed-citation><mixed-citation xml:lang="ru">Rodriguez-Sevilla J.J., Güerri-Fernádez R., Bertran Recasens B. Is There Less Alteration of Smell Sensation in Patients with Omicron SARS-CoV-2 Variant Infection? // Front Med. 2022. Vol. 9. P. 852998. doi: 10.3389/fmed.2022.852998</mixed-citation></citation-alternatives></ref><ref id="B62"><label>62.</label><citation-alternatives><mixed-citation xml:lang="en">Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022; 602(7898):657–663. doi: 10.1038/s41586-021-04385-3</mixed-citation><mixed-citation xml:lang="ru">Cao Y., Wang J., Jian F., et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies // Nature. 2022. Vol. 602, N 7898. P. 657–663. doi: 10.1038/s41586-021-04385-3</mixed-citation></citation-alternatives></ref></ref-list></back></article>
